Hepatitis C can be cured globally, but at what cost?
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
New drugs to cure hepatitis C should be made available at low costs in developing countries
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“with cost-based pricing research similar to this, alongside advocacy groups and political will, treatment courses were brought down to <$100 per 12-week treatment course [31,40].”
From Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment (2023) · cites this paper as [40]
In the citing paper
“when direct-acting antivirals were developed for hepatitis C 10 years ago, courses were $84,000 per person ($1000/pill)”
From Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment (2023) · cites this paper as [40]
Citations
Cites
Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61728-0 · Cited by 14,070
Mohd Hanafiah, K., Groeger, J., Flaxman, A. D., & Wiersma, S. T. (2013) · Hepatology · doi:10.1002/hep.26141 · Cited by 2,515
Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
Sulkowski, M. S., Gardiner, D. F., Rodriguez-Torres, M., Reddy, K. R., Hassanein, T., Jacobson, I., Lawitz, E., Lok, A. S., Hinestrosa, F., Thuluvath, P. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1306218 · Cited by 1,190
The Increasing Burden of Mortality From Viral Hepatitis in the United States Between 1999 and 2007
Ly, K. N., Xing, J., Klevens, R. M., Jiles, R. B., Ward, J. W., & Holmberg, S. D. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-4-201202210-00004 · Cited by 711
Hill, A., Khoo, S., Fortunak, J., Simmons, B., & Ford, N. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu012 · Cited by 216
Self-citationViral hepatitis and the G lobal B urden of D isease: a need to regroup
Cooke, G., Lemoine, M., Thursz, M. R., Gore, C., Swan, T., Kamarulzaman, A., du Cros, P., & Ford, N. P. (2013) · Journal of Viral Hepatitis · doi:10.1111/jvh.12123 · Cited by 122
Self-citationThe 10-year struggle to provide antiretroviral treatment to people with HIV in the developing world
Schwartländer, B., Grubb, I. R., & Perriëns, J. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69164-2 · Cited by 116
Expanding Access to Treatment for Hepatitis C in Resource-Limited Settings: Lessons From HIV/AIDS
Ford, N. P., Singh, K. P., Cooke, G., Mills, E. J., von Schoen-Angerer, T., Kamarulzaman, A., & du Cros, P. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis227 · Cited by 102
Self-citation
Research works printed but not linked: 3
- Medivir, 2012 Annual Report, Stockholm (2012), p. 26.
- MSF Drug Access Team, Untangling the web of antiretroviral price reductions: 16th edition (Geneva, 2012); www.msfaccess.org/reports.
- www.unitaid.org/en/resources/press-centre/releases/1352-unitaid-approves-grants-of-160-million
Cited by
James, S. L., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdela, J., Abdelalim, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32279-7 · Cited by 13,867
Vos, T., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32154-2 · Cited by 13,220
Drug repurposing for antimicrobial discovery
Farha, M. A., & Brown, E. D. (2019) · Nature Microbiology · doi:10.1038/s41564-019-0357-1 · Cited by 360
Levi, J., Wang, J., Venter, F., & Hill, A. (2023) · Obesity · doi:10.1002/oby.23725 · Cited by 69
“research similar to this, alongside advocacy groups and political will, treatment courses were brought down to <$100 per 12-week treatment course [31, 40].”
MethodSelf-citation
Metadata
- Authors
- Hill, A., & Cooke, G.
- Affiliations
- University of Liverpool (GB)
- Imperial College London (GB)
- Venue
- Science
- Published
- 2014-07-11
- Volume
- 345
- Issue
- 6193
- Pages
- 141-142
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2076417435
- Semantic Scholar
- 651a9813304de9dc68370a7cbb70bf5edd7fbd03
- Cited by
- 65
- References
- 8
- Citations by year
- 2025: 2 · 2024: 1 · 2023: 1 · 2021: 5 · 2020: 1 · 2019: 4 · 2018: 5 · 2017: 6 · 2016: 16 · 2015: 19 · 2014: 5
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Medical Research Council (MR/K01532X/1)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatitis C virus research
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- hepatitis C, antiviral agents, drug pricing, access to medicines, developing countries, global health, treatment costs
- MeSH terms
- Sofosbuvir, Simeprevir, Antiviral Agents, Developing Countries, Hepatitis C, Heterocyclic Compounds, 3-Ring, Humans, Sulfonamides, Uridine Monophosphate, Global Health, Drug Costs, Drugs, Generic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.